Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Camrelizumab · SHR-1210

Monoclonal antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) · developed by Jiangsu HengRui Medicine Co.

Phase 2/3 Most advanced trial
1 Registered trials

What is Camrelizumab?

Camrelizumab is a monoclonal antibody that binds the PD-1 receptor on activated T cells, B cells and natural killer cells, blocking its interaction with PD-L1 and PD-L2. This prevents PD-1 signaling and restores cytotoxic T-lymphocyte responses against tumor cells. It is studied in metastatic pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SHR-1210
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PDCD1), Programmed cell death 1 ligand 1 (CD274) (binding partner it blocks), Programmed cell death 1 ligand 2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1)
Pathways
PD-1 downstream signaling, cytotoxic T-lymphocyte activation
Therapy area
Oncology
Developer
Jiangsu HengRui Medicine Co., Ltd.
In trials of
HCM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
73096E137E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06361888 Phase 2/3 Metastatic Pancreatic Cancer Recruiting HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Pancreatic Cancer

Other drugs acting on PDCD1

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.